|
Sukanto Sinha, Ph.D., co-founder and CEO, has over 27 years of pharma/startup experience in target discovery & validation, and drug discovery & development. Prior to co-founding ActiveSite, he was Vice President, Biology at Elan Pharmaceuticals (previously Athena Neurosciences). Dr. Sinha led the team that discovered BACE, a key enzyme involved in amyloid plaque formation in Alzheimer’s Disease. He subsequently managed Elan’s multi-disciplinary team of over 40 scientists including chemists, pharmacologists and biologists in a collaboration between Elan and Pharmacia for development of small-molecule drug candidates targeting BACE. With over 40 publications and inventorship on 33 US patents, Dr. Sinha is an expert on proteases and developing small molecule inhibitors of proteases. Dr. Sinha holds a B.Sc. (Honors) in chemistry from IIT (Kharagpur, India) and a Ph.D. in biochemistry from the University of Georgia (Athens, GA, USA).
Tamie Chilcote, Ph.D., co-founder and COO, has over 21 years of experience in target discovery & validation, and drug discovery & development. Prior to co-founding ActiveSite, she was a Principal Scientist at Elan Pharmaceuticals (previously Athena Neurosciences). Dr. Chilcote led team efforts on both Alzheimer’s and Parkinson’s Disease at Elan. Importantly, she identified disease-specific modifications of the Parkinson’s Disease protein alpha-synuclein, and specific antibodies directed to alpha-synuclein, one of which is in clinical development. Dr. Chilcote has over 20 publications and is an inventor on 14 US patents. Dr. Chilcote has a B.S. and Ph.D. in biochemistry from the Pennsylvania State University (State College, PA, USA).
|